288 related articles for article (PubMed ID: 34069206)
1. Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2.
Tonk M; Růžek D; Vilcinskas A
Viruses; 2021 May; 13(5):. PubMed ID: 34069206
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial and Amyloidogenic Activity of Peptides. Can Antimicrobial Peptides Be Used against SARS-CoV-2?
Kurpe SR; Grishin SY; Surin AK; Panfilov AV; Slizen MV; Chowdhury SD; Galzitskaya OV
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333996
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial peptides: A promising tool to combat multidrug resistance in SARS CoV2 era.
Saini J; Kaur P; Malik N; Lakhawat SS; Sharma PK
Microbiol Res; 2022 Dec; 265():127206. PubMed ID: 36162150
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial peptides for novel antiviral strategies in the current post-COVID-19 pandemic.
Loffredo MR; Nencioni L; Mangoni ML; Casciaro B
J Pept Sci; 2024 Jan; 30(1):e3534. PubMed ID: 37501572
[TBL] [Abstract][Full Text] [Related]
5. Molecular Docking and In-Silico Analysis of Natural Biomolecules against Dengue, Ebola, Zika, SARS-CoV-2 Variants of Concern and Monkeypox Virus.
Dassanayake MK; Khoo TJ; Chong CH; Di Martino P
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232431
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial peptides and other peptide-like therapeutics as promising candidates to combat SARS-CoV-2.
Mousavi Maleki MS; Rostamian M; Madanchi H
Expert Rev Anti Infect Ther; 2021 Oct; 19(10):1205-1217. PubMed ID: 33844613
[No Abstract] [Full Text] [Related]
7. Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs.
Zannella C; Chianese A; Palomba L; Marcocci ME; Bellavita R; Merlino F; Grieco P; Folliero V; De Filippis A; Mangoni M; Nencioni L; Franci G; Galdiero M
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216177
[TBL] [Abstract][Full Text] [Related]
8. Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation.
Di Micco S; Musella S; Sala M; Scala MC; Andrei G; Snoeck R; Bifulco G; Campiglia P; Fasano A
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502335
[TBL] [Abstract][Full Text] [Related]
9. Molnupiravir and Its Antiviral Activity Against COVID-19.
Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
Front Immunol; 2022; 13():855496. PubMed ID: 35444647
[TBL] [Abstract][Full Text] [Related]
10. Chemically modified antiviral peptides against SARS-CoV-2.
Quagliata M; Papini AM; Rovero P
J Pept Sci; 2024 Feb; 30(2):e3541. PubMed ID: 37699615
[TBL] [Abstract][Full Text] [Related]
11. Human Antimicrobial Peptides as Therapeutics for Viral Infections.
Ahmed A; Siman-Tov G; Hall G; Bhalla N; Narayanan A
Viruses; 2019 Aug; 11(8):. PubMed ID: 31374901
[TBL] [Abstract][Full Text] [Related]
12. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.
Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ
J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962
[TBL] [Abstract][Full Text] [Related]
13. Rediscovery of antimicrobial peptides as therapeutic agents.
Ryu M; Park J; Yeom JH; Joo M; Lee K
J Microbiol; 2021 Feb; 59(2):113-123. PubMed ID: 33527313
[TBL] [Abstract][Full Text] [Related]
14. Antiviral Strategies Using Natural Source-Derived Sulfated Polysaccharides in the Light of the COVID-19 Pandemic and Major Human Pathogenic Viruses.
Ray B; Ali I; Jana S; Mukherjee S; Pal S; Ray S; Schütz M; Marschall M
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062238
[TBL] [Abstract][Full Text] [Related]
15. Harnessing the Therapeutic Potential and Biological Activity of Antiviral Peptides.
Guarracino DA; Iannaccone J; Cabrera A; Kancharla S
Chembiochem; 2022 Oct; 23(20):e202200415. PubMed ID: 36075015
[TBL] [Abstract][Full Text] [Related]
16. Screening of Severe Acute Respiratory Syndrome Coronavirus 2 RNA-Dependent RNA Polymerase Inhibitors Using Computational Approach.
Dhankhar P; Dalal V; Kumar V
J Comput Biol; 2021 Dec; 28(12):1228-1247. PubMed ID: 34847746
[TBL] [Abstract][Full Text] [Related]
17. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
18. Natural Products and Nutrients against Different Viral Diseases: Prospects in Prevention and Treatment of SARS-CoV-2.
Ali SG; Ansari MA; Alzohairy MA; Almatroudi A; Alomary MN; Alghamdi S; Rehman S; Khan HM
Medicina (Kaunas); 2021 Feb; 57(2):. PubMed ID: 33673004
[TBL] [Abstract][Full Text] [Related]
19. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
20. Fusion Protein Targeted Antiviral Peptides: Fragment-Based Drug Design (FBDD) Guided Rational Design of Dipeptides Against SARS-CoV-2.
Manna S; Chowdhury T; Baindara P; Mandal SM
Curr Protein Pept Sci; 2020; 21(10):938-947. PubMed ID: 32901582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
